The role of p53 on survival of upper urinary tract urothelial carcinoma: A systematic review and meta-analysis

Clinical Genitourinary Cancer

Volumn 11, Issue 3, 2013, Pages 221-228

  Ku, Ja Hyeon ^a   Byun, Seok Soo ^b   Jeong, Hyeon ^c   Kwak, Cheol ^a   Kim, Hyeon Hoe ^a   Lee, Sang Eun ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Meta analysis; p53; Prognosis; Renal pelvis; Upper urinary tract; Ureter; Urothelial carcinoma

Indexed keywords

PROTEIN P53;

CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA;

META-ANALYSIS; P53; PROGNOSIS; RENAL PELVIS; UPPER URINARY TRACT; URETER; UROTHELIAL CARCINOMA;

HUMANS; PROGNOSIS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY TRACT; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84883352856     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.12.009     Document Type: Review

References (50)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. J.D. Raman, J. Messer, J.A. Sielatycki Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005 BJU Int 107 2011 1059 1064
3. G. Lughezzani, M. Burger, V. Margulis Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature Eur Urol 62 2012 100 114
4. S.F. Shariat, P.I. Karakiewicz, R. Ashfaq Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 112 2008 315 325
5. B.J. Schmitz-Dräger, P.J. Goebell, T. Ebert p53 immunohistochemistry as a prognostic marker in bladder cancer Playground for urology scientists? Eur Urol 38 2000 691 699
6. N. Malats, A. Bustos, C.M. Nascimento P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 2005 678 686
7. W.M. Stadler, S.P. Lerner, S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
8. S. Mitchell, E. Mayer, A. Patel Expression of p53 in upper urinary tract urothelial carcinoma Nat Rev Urol 8 2011 516 522
9. D.G. Altman, R.D. Riley Primer: an evidence-based approach to prognostic markers Nat Clin Pract Oncol 2 2005 466 472
10. P. de Graeff, A.P. Crijns, S. de Jong Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159
11. D.F. Hayes, R.C. Bast, C.E. Desch Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers J Natl Cancer Inst 88 1996 1456 1466
12. L.M. McShane, D.G. Altman, W. Sauerbrei REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 2005 387 391
13. M.K. Parmar, V. Torri, L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
14. P.R. Williamson, C.T. Smith, J.L. Hutton Aggregate data meta-analysis with time-to-event outcomes Stat Med 21 2002 3337 3351
15. J.F. Tierney, L.A. Stewart, D. Ghersi Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
16. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
17. J.P. Higgins, S.G. Thompson, J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
18. K. Nakanishi, S. Tominaga, T. Kawai Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract Virchows Arch 432qj 1998 445 450
19. K. Nakanishi, T. Kawai, S. Hiroi Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract Cancer 86 1999 2109 2116
20. K. Nakanishi, S. Tominaga, S. Hiroi Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract Virchows Arch 441 2002 559 563
21. K. Nakanishi, S. Hiroi, S. Tominaga Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract Clin Cancer Res 11 2005 2583 2590
22. P.P. Bringuier, M. McCredie, G. Sauter Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes Int J Cancer 79 1998 531 536
23. J. Watanabe, H. Nishiyama, H. Kawanishi Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors J Urol 174 2005 73 75
24. L. Izquierdo, L. Mengual, C. Gazquez Molecular characterization of upper urinary tract tumours BJU Int 106 2010 868 872
25. H. Hashimoto, Y. Sue, Y. Saga Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter Int J Urol 7 2000 457 463
26. S. Kamijima, T. Tobe, T. Suyama The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter Int J Urol 12 2005 941 947
27. I.G. Jeong, S.H. Kim, H.G. Jeon Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract Hum Pathol 40 2009 668 677
28. M. Furihata, Y. Ohtsuki, H. Sonobe Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter Br J Cancer 77 1998 783 788
29. T. Okamura, K. Ueda, Y. Hashimoto Immunohistochemical evaluation of p53 and retinoblastoma proteins in relation to hyperthermia treatment: results in human urothelial carcinomas Int J Hyperthermia 12 1996 813 824
30. R.B. Terrell, J.C. Cheville, W.A. See Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis J Urol 154 1995 1342 1347
31. K. Nakanishi, T. Kawai, C. Torikata Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract Hum Pathol 27 1996 1336 1340
32. A. Rey, P.C. Lara, E. Redondo Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter Relation to tumor proliferation and survival Cancer 79 1997 2178 2185
33. S. Jinza, Y. Takano, M. Iki Prognostic significance of p53 protein overexpression in transitional cell carcinoma of the renal pelvis and ureter Urol Int 60 1998 147 151
34. R. Zigeuner, O. Tsybrovskyy, M. Ratschek Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma Urology 63 2004 1079 1083
35. G. Fromont, M. Rouprêt, N. Amira Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma Eur Urol 48 2005 764 770
36. S. Scarpini, M. Rouprêt, R. Renard-Penna Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract Urol Oncol 30 2012 182 187
37. P. Hainaut, M. Hollstein p53 and human cancer: the first ten thousand mutations Adv Cancer Res 77 2000 81 137
38. M. Hollstein, D. Sidransky, B. Vogelstein p53 mutations in human cancers Science 253 1991 49 53
39. D. Wynford-Thomas P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 166 1992 329 330
40. G. Levidou, E. El-Habr, A.A. Saetta P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature J Neuroncol 100 2010 363 371
41. J.M. Wolff, R.N. Stephenson, G. Jakse Retinoblastoma and p53 genes as prognostic indicators in urological oncology Urol Int 53 1994 1 5
42. P.K. Lipponen Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value Int J Cancer 53 1993 365 370
43. D. Esrig, C.H. Spruck III, P.W. Nichols p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer Am J Pathol 143 1993 1389 - 97.45
44. L.A. Stewart, M.K. Parmar Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341 1993 418 422
45. D.G. Altman, B. Lausen, W. Sauerbrei Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829 835
46. M. Egger, T. Zellweger-Zähner, M. Schneider Language bias in randomised controlled trials published in English and German Lancet 350 1997 326 329
47. D.F. Hayes, C. Isaacs, V. Stearns Prognostic factors in breast cancer: current and new predictors of metastasis J Mammary Gland Biol Neoplasia 6 2001 375 392
48. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder Urol Oncol 25 2007 468 475
49. A.B. Als, L. Dyrskjøt, H. von der Maase Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer Clin Cancer Res 13 2007 4407 4414
50. J.A. Karam, Y. Lotan, P.I. Karakiewicz Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy Lancet Oncol 8 2007 128 136